Proton range uncertainty reduction benefits for skull base tumors in terms of normal tissue complication probability (NTCP) and healthy tissue doses
| Autor: | Sebastian Tattenberg, J Verburg, T Madden, Katia Parodi, Bram L. Gorissen, Thomas Bortfeld |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Organs at Risk
medicine.medical_specialty medicine.medical_treatment Optic chiasm Skull Base Neoplasms Range (statistics) Proton Therapy Medicine Humans Proton therapy Uncertainty reduction theory Probability business.industry Radiotherapy Planning Computer-Assisted Uncertainty Percentage point Radiotherapy Dosage General Medicine Radiation therapy Skull medicine.anatomical_structure Radiology Radiotherapy Intensity-Modulated Protons business Complication |
| Zdroj: | Medical physicsREFERENCES. 48(9) |
| ISSN: | 2473-4209 |
| Popis: | Purpose Proton therapy allows for more conformal dose distributions and lower organ at risk and healthy tissue doses than conventional photon-based radiotherapy, but uncertainties in the proton range currently prevent proton therapy from making full use of these advantages. Numerous developments therefore aim to reduce such range uncertainties. In this work, we quantify the benefits of reductions in range uncertainty for treatments of skull base tumors. Methods The study encompassed 10 skull base patients with clival tumors. For every patient, six treatment plans robust to setup errors of 2 mm and range errors from 0% to 5% were created. The determined metrics included the brainstem and optic chiasm normal tissue complication probability (NTCP) with the endpoints of necrosis and blindness, respectively, as well as the healthy tissue volume receiving at least 70% of the prescription dose. Results A range uncertainty reduction from the current level of 4% to a potentially achievable level of 1% reduced the probability of brainstem necrosis by up to 1.3 percentage points in the nominal scenario in which neither setup nor range errors occur and by up to 2.9 percentage points in the worst-case scenario. Such a range uncertainty reduction also reduced the optic chiasm NTCP with the endpoint of blindness by up to 0.9 percentage points in the nominal scenario and by up to 2.2 percentage points in the worst-case scenario. The decrease in the healthy tissue volume receiving at least 70% of the prescription dose ranged from -7.8 to 24.1 cc in the nominal scenario and from -3.4 to 38.4 cc in the worst-case scenario. Conclusion The benefits quantified as part of this study serve as a guideline of the OAR and healthy tissue dose benefits that range monitoring techniques may be able to achieve. Benefits were observed between all levels of range uncertainty. Even smaller range uncertainty reductions may therefore be beneficial. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text